Technological Growth Opportunities for Exosome-Mediated Drug Delivery Market Research Study 2022 – Increasing R&D Collaborations and New Therapeutic Pipelines –

DUBLIN–(BUSINESS WIRE)–Added the Technology Growth Opportunities for Exosome-Mediated Drug Delivery report Offer.

This research provides an overview of the emerging modalities provided by exosomes in pre-clinical or clinical stages, highlighting technological roadmaps, market trends and the latest research findings.

The study discusses the various routes of administration for injecting these components into the human body and the notable R&D collaborations and licensing agreements among pharmaceutical companies, biotechnology companies and academic partners for post-technology transfer commercial product development.

Codiak BioSciences, Capricor Therapeutics and Evox Therapeutics are among the key companies with many pipeline candidates, significant investments and strategic R&D partnerships in the area of ​​exosome-mediated drug delivery for disease indications such as cancer, COVID-19, rare diseases and neurological disorders. This study completes the analysis with growth opportunities for clinical translation of exosome nanocarriers.

Exosome-mediated drug delivery is a promising alternative to traditional drug delivery methods that is making rapid progress in the biopharmaceutical industry due to the safety and efficacy advantages that exosomes as nanocarriers offer over synthetic nanoparticles. The widely explored concepts of nanomedicine, nucleic acid therapeutics, and cell-free vaccines have supported the incorporation of exosomes into the delivery of new drug modalities.

Non-immunogenicity, biocompatibility and stability are key features that make exosomes attractive as carriers in the biopharmaceutical sector. As such, microRNAs, small interfering RNAs, the CRISPR-Cas9 system, viral vectors, antisense oligonucleotides, messenger RNA (mRNA) vaccines, heteroduplexes, surface antigens, and proteinaceous antibodies have emerged as delivery modalities that are either endogenous or exogenous to natural or artificially packaged exosomes.

Exosomes alleviate the problems of stability, low bioavailability, off-targeting, reduced genetic expression, membrane uptake, and cellular degradation faced by other nanocarriers in drug modality delivery. There is a growing body of research and clinical evidence supporting the immense value of exosomes in delivering mRNA vaccines, gene editing tools, gene therapy, and disease-related small proteins to treat life-threatening conditions.

Exosomes are also used to develop mRNA and other advanced therapeutic formulations that can be delivered in more patient-friendly ways, e.g. B. orally and intranasally. These extracellular vesicles are surface engineered to maximize payload efficiency and targeted delivery.

Increasing research and development on exosome delivery specificity, cellular uptake and signaling is accelerating the development of novel exosome-mediated drug delivery technologies for improved patient outcomes. The United States has emerged as the center of the exosome-mediated drug delivery industry, with many private and academic institutions conducting research and technology deployment.

Europe is also witnessing a significant amount of R&D activity as intensive collaborations accelerate the development of exosomes as nanocarriers. The scalability of exosome production remains an issue, but biotechnology companies are tackling it by building novel manufacturing platforms and exploring newer sources of extracellular vesicles. These drivers have opened new growth opportunities for access to non-drug targets related to rare and deadly diseases.

Main topics covered:

1 Strategic imperatives

  • Why is it getting harder and harder to grow? Factors creating growth pressure

  • The strategic imperative

  • The Impact of the Top 3 Strategic Imperatives on the Exosome-Mediated Drug Delivery Industry

  • Growth opportunities fuel the growth pipeline engine

2 Growth Opportunity Analysis

  • Scope of Analysis

  • segmentation

  • research methodology

  • Exosomes are EVs with targeted delivery potential

  • growth accelerator

  • growth restrictions

  • Expansion of R&D collaborations and emerging therapeutic pipelines with exosome-based delivery

3 Technology Snapshot: Exosome-mediated drug delivery

  • Exosomes are the most promising nanocarriers

  • Innate stability, low immunogenicity, and biocompatibility drive the use of exosomes as nanocarriers

  • MEs and engineered exosomes are gaining traction

  • Increasing adoption of chemical conjugation methods to encapsulate biomolecules in exosomes

  • Intranasal and oral administration as patient-conformant routes

  • The surface engineering of exosomes is important for targeted delivery to organs

4 Innovation Landscape: New Modalities for Exploiting Exosomes

  • New therapeutic modalities using exosomes

  • Endogenously loaded exosomes for mRNA vaccine delivery are promising alternatives to LNP vehicles

  • Exosome-based mRNA vaccines for infectious diseases

  • Promising non-viral carriers for gene therapy and editing

  • Exosome R&D delivers CRISPR-Cas9 for gene editing

  • Prevalence of exosome-mediated delivery of RNAi therapeutics using endogenous loading

  • Exosome-mediated delivery of RNAi molecules is widely accepted

  • Endogenous loading of exosomes with small proteins for inflammatory pathways

  • R&D partnerships focused on inflammation-associated small protein delivery

  • Exogenous loading of exosomes improves targeted delivery

  • Codiak BioSciences delivers most of its cargo through exogenous loading

  • Intranasal and oral routes of administration are primed for growth

  • Nasally delivered exosomes show promise for vaccine delivery and CNS targeting

5 Market Analysis, Funding Landscape, Mergers and Acquisitions

  • Increasing R&D collaborations and licensing agreements between exosome therapeutics/suppliers and leading pharmaceutical participants

  • Recent R&D collaborations indicate a growing body of work in CNS targeting and gene therapy delivery

  • The deployment of COVID-19 mRNA vaccines has attracted significant VC and federal funding

  • Emerging trends in exosome drug delivery

6 growth opportunities universe

  • Growth Opportunity 1: Mass production of artificial exosomes that mimic natural exosomes for drug delivery

  • Growth Opportunity 2: Autologous Exosomes in Personalized Cancer Immunotherapy

  • Growth opportunity 3: Cooperations between Exosome Manufacturing Services and pharmaceutical companies

7 Appendix

  • The number of visitors to the ExoCarta database has increased over the past decade

  • Surface presentation of fusion proteins binds the exogenous cargo

  • Notable Patents

For more information about this report, visit


Leave a Reply

Your email address will not be published. Required fields are marked *